The development and evaluation of a nanovesicular transdermal formulation of asenapine maleate, with the specific goal of targeting the brain. Asenapine maleate is a medication used for the treatment of certain neurological disorders, and the research aims to enhance its delivery to the brain through a novel transdermal approach. Nanovesicular transdermal formulations offer a promising means of drug delivery, as they can bypass the blood-brain barrier and directly target the brain tissues. This study involves the design and optimization of nanovesicular carriers to encapsulate asenapine maleate, enabling its efficient transport through the skin and into the brain. Researchers conduct thorough evaluations to assess the stability, drug release kinetics, and skin permeation capabilities of the nanovesicular formulation. Additionally, they investigate its safety and efficacy in animal models or potentially in clinical trials, exploring its potential for use as a non-invasive and patient-friendly alternative to conventional drug delivery methods. By successfully developing a nanovesicular transdermal formulation of asenapine maleate for brain targeting, this research could pave the way for significant advancements in treating neurological disorders. The findings have the potential to revolutionize drug delivery strategies, offering a more effective and convenient treatment approach for patients in need of brain-specific medications.